SLNSW-Evorpacept alone and in combination with pembroli...-TN_cdi_proquest_journals_2604389446

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

Full title: Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

Author/creator: Lakhani, Nehal J, Chow, Laura Q M, Gainor, Justin F, LoRusso, Patricia, Lee, Keun-Wook, Chung, Hyun Cheol, Lee, Jeeyun, Bang, Yung-Jue, Hodi, Frank Stephen, Kim, Won Seog, Santana-Davila, Rafael, Fanning, Philip, Squifflet, Pierre, Jin, Feng, Kuo, Tracy C, Wan, Hong I, Pons, Jaume, Randolph, Sophia S, Messersmith, Wells A.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_2604389446

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2604389446

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

    Record identifier

    TN_cdi_proquest_journals_2604389446

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2604389446

    Share

    Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2604389446

    Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

    Full title

    Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

    Author / Creator

    Lakhani, Nehal J ; Chow, Laura Q M ; Gainor, Justin F ; LoRusso, Patricia ; Lee, Keun-Wook ; Chung, Hyun Cheol ; Lee, Jeeyun ; Bang, Yung-Jue ; Hodi, Frank Stephen ; Kim, Won Seog ; Santana-Davila, Rafael ; Fanning, Philip ; Squifflet, Pierre ; Jin, Feng ; Kuo, Tracy C ; Wan, Hong I ; Pons, Jaume ; Randolph, Sophia S ; Messersmith, Wells A

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2021, Vol.22 (12), p.1740-1751

    Record Identifier

    TN_cdi_proquest_journals_2604389446

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Adaptive immunity Adverse events Aged Analysis Antibodies, Monoclonal, Humanized - administration & dosage Antigens Antimitotic agents Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Cancer therapies Care and treatment Chemotherapy Clinical trials Cytotoxicity Dendritic cells Drug dosages ErbB-2 protein Female Follow-Up Studies Head and neck carcinoma Hematology Humans Immune response Immunoglobulin Fc Fragments - administration & dosage Immunoglobulin G Immunosurveillance Immunotherapy Intravenous administration Lung cancer Lymphoma Male Maximum Tolerated Dose Medical research Metastases Metastasis Middle Aged Monoclonal antibodies Neoplasms - drug therapy Neoplasms - pathology Neutropenia Non-small cell lung carcinoma Oncology Pancreatic cancer Patients Pembrolizumab Pharmacodynamics Pharmacokinetics Prognosis Proteins Safety Small cell lung carcinoma Solid tumors Squamous cell carcinoma Targeted cancer therapy Thrombocytopenia Toxicity Trastuzumab Trastuzumab - administration & dosage Tumors

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_2604389446

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2604389446

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections